Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | RBP4 | P02753 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.34 |
| ▸ | LIPE | Q05469 | 2/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602166 | 0.89 | GPR119 (0.49) | GPR119 | |
| SCHEMBL4566643 | 0.86 | KCNH2 (0.33) | HRH3KCNH2FFAR4 | |
| SCHEMBL3602342 | 0.81 | GPR119 (0.39) | HRH3GPR119KMT2AEPHX2BTK | |
| SCHEMBL3602573 | 0.81 | HRH3 (0.43) | HRH3GPR119KMT2ALOXL2EPHX2 | |
| SCHEMBL3610594 | 0.80 | LOXL2 (0.44) | KMT2ALOXL2EPHX2BTKKCNH2 | |
| SCHEMBL3248797 | 0.79 | GPR119 (0.36) | HRH3GPR119LOXL2EPHX2BTK | |
| SCHEMBL5266382 | 0.77 | HRH3 (0.46) | HRH3GPR119EPHX2BTKKCNH2 | |
| SCHEMBL5270350 | 0.76 | HCRTR1 (0.44) | GPR119KMT2AEPHX2BTKKCNH2 | |
| SCHEMBL3607859 | 0.75 | CYP2D6 (0.38) | KMT2A | |
| SCHEMBL4129398 | 0.75 | KCNH2 (0.45) | GPR119LOXL2EPHX2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723331-B2 | Thienopyrimidine compounds and uses thereof | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| US-20080051405-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051405-A1 | Therapeutic Agents | GPR119, HTT, IAPP | HRH3 1346/4885GPR119 1/4885KMT2A 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.